![]() | |
Clinical data | |
---|---|
Trade names | Visipaque |
Other names | 5-[acetyl-[3-[acetyl-[3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodo-phenyl]amino]-2-hydroxy-propyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide |
AHFS/Drugs.com | Multum Consumer Information |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | Negligible |
Metabolism | Excreted unchanged |
Elimination half-life | 2.1 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.124.306 |
Chemical and physical data | |
Formula | C35H44I6N6O15 |
Molar mass | 1550.191 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Iodixanol, sold under the brand name Visipaque, is an iodine-containing non-ionic radiocontrast agent. [2]
It is available as a generic medication. [3] [4]
The radio contrast agent is given intravenously for computed tomography (CT) imaging of the head, body, excretory urography and venography. The radiocontrast agent is also given intra-arterially for angiography imaging. [5]
About 30% of those received intravenous iodixanol injection has warmth, pain, or discomfort at the site of the injection. Other adverse effects include: taste perversion (3.5%), nausea (2.8%), and headache (2.5%). [5]
The contrast can either be given intra-arterialy or intravenously. [5]
Iodixanol is also the active ingredient in a number of 'cushion' products used during the centrifugation of stallion semen. It is layered underneath the extended stallion semen allowing for a higher g force to be used with less sperm damage and better recovery rates. Post centrifugation the supernatant above and the cushion below is removed, leaving a concentrated sperm pellet in the conical tube. [6]